Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
C
Clyde Bailey
Director of Bioinformatics
Also affiliated: Thomas Jefferson University (2012); University of Arkansas Medical Center (2025); University Medical Center Utrecht (2019); Cancer Research And Biostatistics (2012); Sidney Kimmel Cancer Center (2012)
14 h-index
93 pubs
585 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Clyde Bailey's research focuses on multiple myeloma, investigating its underlying mechanisms and potential therapeutic strategies. His work includes examining the immune microenvironment's alterations in multiple myeloma and its precursor stages, as well as identifying specific gene expressions, such as NEK2, that may suppress T-cell immunity. Bailey also studies the predictive value of gene signatures for disease progression and explores the feasibility of outpatient stem cell transplantation for multiple myeloma patients, identifying risk factors for hospital admission. His collaborative efforts at the University of Arkansas for Medical Sciences involve extensive work with researchers like Fenghuang Zhan, John D. Shaughnessy, and Guido Tricot, evidenced by numerous shared publications. Bailey's scholarship metrics include an h-index of 14, 95 total publications, and 1,943 total citations.
Metrics
- h-index: 14
- Publications: 93
- Citations: 585
Positions
-
Director of Bioinformatics 1998–presentUAMS Medicine ORCID
Selected Publications
-
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 -6 . (2026)
-
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)
-
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)
-
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)
-
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)
-
CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients (2024)
-
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)
Collaboration Network
Top Collaborators
Frits van Rhee
University of Arkansas for Medical Sciences
53 shared publications
In database
- Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 53 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
47 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
Showing 5 of 47 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
39 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 39 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
39 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 39 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
33 shared publications
In database
- Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
- Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Showing 5 of 33 shared publications
Samer Al Hadidi
Southwestern Medical Center
30 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 30 shared publications
John D. Shaughnessy
Winthrop Rockefeller Foundation
27 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
- Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
- Suppression of abnormal karyotype predicts superior survival in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 27 shared publications
Guido J. K. Tricot
University of Arkansas for Medical Sciences
21 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 21 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
18 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 18 shared publications
Jeffrey R. Sawyer
University of Arkansas for Medical Sciences (US)
16 shared publications
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
- Suppression of abnormal karyotype predicts superior survival in multiple myeloma
Showing 5 of 16 shared publications
Daisy V. Alapat
University of Arkansas Medical Center
16 shared publications
In database
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 16 shared publications
Christoph Johann Heuck
University of Arkansas for Medical Sciences (US)
16 shared publications
- Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
- The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma
Showing 5 of 16 shared publications
David E. Mery
University of Arkansas for Medical Sciences
16 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
Showing 5 of 16 shared publications
Joshua Epstein
University of Arkansas for Medical Sciences (US)
15 shared publications
- Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
Showing 5 of 15 shared publications
Fenghuang Zhan
University of Arkansas for Medical Sciences
15 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 15 shared publications
Similar Researchers
Based on overlapping research topics
Medhavi Honhar
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Immune Response and Inflammation
Md Shadiqul Hoque
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Ankur Varma
University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation
Immune Response and Inflammation
Cancer Treatment and Pharmacology
David E. Mery
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Hematopoietic Stem Cell Transplantation
Michael Bauer
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Bioinformatics and Genomic Networks
Ahmad Mazen Safar
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology